United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

atnahs pharma uk ltd - lisinopril - oral tablet - 5mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

atnahs pharma uk ltd - lisinopril - oral tablet - 10mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

atnahs pharma uk ltd - lisinopril - oral tablet - 20mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

atnahs pharma uk ltd - naproxen - oral tablet - 250mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

atnahs pharma uk ltd - naproxen - oral tablet - 500mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

atnahs pharma uk ltd - naproxen - gastro-resistant tablet - 250mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

atnahs pharma uk ltd - naproxen - gastro-resistant tablet - 500mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

atnahs pharma uk ltd - olsalazine sodium - oral capsule - 250mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

atnahs pharma uk ltd - olsalazine sodium - oral tablet - 500mg

Australia - English - Department of Health (Therapeutic Goods Administration)

atnahs pharma australia pty ltd - famciclovir, quantity: 500 mg - tablet, film coated - excipient ingredients: sodium starch glycollate; hyprolose; magnesium stearate; titanium dioxide; hypromellose; macrogol 6000; macrogol 4000 - famvir is indicated for the treatment of herpes zoster infection in adult patients who commence therapy within 72 hours of the onset of the rash. greatest benefit occurs if the drug is started within 48 hours. efficacy has not been demonstrated in patients less than 50 years of age, although the occasional younger patient with severe herpes zoster may benefit from therapy with famciclovir. herpes zoster is generally a milder condition in younger patients. famvir is also indicated in the treatment of recurrent episodes of genital herpes in adults and adolescents 12 years of age and older. famvir is also indicated for suppression of recurrent genital herpes. famvir is also indicated for the treatment of recurrent herpes labialis (cold sores) in immunocompetent patients famvir is also indicated in immunocompromised patients for: treatment of uncomplicated herpes zoster; treatment of recurrent herpes simplex; suppression of recurrent herpes simplex